SVRA Savara Inc. logo

SVRA Savara Inc.

Healthcare
$5.02-0.79%ClosedMarket Cap: $1.03B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

7.22

P/S

0.00

EV/EBITDA

-7.66

DCF Value

$-0.00

FCF Yield

-10.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-87.2%

ROA

-58.4%

ROIC

-65.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-37.3M$
Q4 null$0.00$-32.2M$
FY null$0.00$-118.8M$
Q3 null$0.00$-29.6M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-12-23
Wells FargoOverweight
2025-12-18
OppenheimerOutperform
2025-11-14
CitizensMarket Outperform
2025-11-13
JMP SecuritiesMarket Outperform
2025-10-23

Trading Activity

Insider Trades

View All
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.28

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Peers